A planned interim analysis of 40 patients reported an 86 percent pain response to 4 Gy, with 18 percent requesting reirradiation. Because 4 Gy may be given in a single fraction, the question is not treatment burden but whether half the conventional dose is sufficient.
A phase I study safely escalated five-fraction stereotactic boosts to 30-35 Gy after recent prior radiotherapy, with 86.5% one-year local control.
Adjuvant radiotherapy did not improve recurrence-free or overall survival, but concurrent systemic therapy did not increase radiotherapy-related toxicity.
Radical radiotherapy use nearly doubled while five-year lung cancer-specific survival rose from 21.9% to 33.1% across Northern Ireland.
Patients reported greater symptom burden than clinicians in 84% of matched domains, with the largest gaps in psychological and less visible symptoms.
NRG-GU003 established noninferiority of 62.5 Gy in 25 fractions for patient-reported genitourinary and gastrointestinal symptoms at two years. The five-year analysis addresses the endpoints for which the trial was not designed
SBRT can provide high local control in selected oligometastatic pancreatic cancer, but randomized survival evidence and patient-selection criteria remain limited.
CBCT detected breast edema in 37.1% during 26 Gy in five fractions, usually immediately after the first treatment.
Contemporary evidence supports contralateral parotid mean dose as the most robust xerostomia predictor, with risk rising around 24–26 Gy.
After the prospective PAM50 signal in NRG-GU006/BALANCE, SPPORT offers an independent test of whether molecular subtype predicts benefit from short-term androgen deprivation — and potentially pelvic nodal radiotherapy.
After resection of ipsilateral recurrence, five-year locoregional recurrence-free survival was 84.2%, while grade 3 late toxicity was 3.9%.
A best MRI model reached AUC 0.91, but across 366 configurations radiomics did not consistently outperform a simple clinical model.
Across 14 studies, repeat stereotactic radiotherapy achieved 76% one-year local control, but symptomatic radiation necrosis occurred in 10%.
With 42.56 Gy in 16 fractions, three-year lymphedema was 6.4%, with no new events through five years.
Bragg peak FLASH achieved high ultra-high-dose-rate coverage with similar target coverage to conventional IMPT, but produced higher target and CNS hotspots.